Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Vildagliptin prevents the inactivation of GLP-1 and GIP by DPP-4, enabling GLP-1 and GIP to enhance insulin secretion from beta cells and reduce glucagon release from alpha cells within islets of Langerhans in the pancreas.